The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in …

…, SG Eckhardt, KD Lewis, KH Brown, MV Cantarini… - Clinical Cancer …, 2010 - AACR
Purpose: In part A, the aim was to define the maximum tolerated dose (MTD) of the hydrogen
sulfate (Hyd-Sulfate) oral capsule formulation of the mitogen-activated protein kinase …

Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor …

PA Dickinson, MV Cantarini, J Collier, P Frewer… - Drug Metabolism and …, 2016 - ASPET
Preclinical and clinical studies were conducted to determine the metabolism and pharmacokinetics
of osimertinib and key metabolites AZ5104 and AZ7550. Osimertinib was designed …

Effect of itraconazole on the pharmacokinetics of rosuvastatin

…, DW Schneck, MV Cantarini - Clinical …, 2003 - Wiley Online Library
Background Rosuvastatin is a new 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA)
reductase inhibitor. Itraconazole, an inhibitor of cytochrome P450 (CYP) 3A4 and the transport …

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

HC Swaisland, MV Cantarini, R Fuhr, A Holt - Clinical pharmacokinetics, 2006 - Springer
Background and objectives Exposure to gefitinib (IRESSAź, ZD1839), an epidermal growth
factor receptor-tyrosine kinase inhibitor, is highly variable between subjects. In an attempt to …

Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors

…, H Swaisland, MR Farmer, MV Cantarini… - International journal of …, 2007 - Elsevier
PURPOSE: To investigate whether differences in plasma pharmacokinetic profiles of
gefitinib between healthy subjects having normal (N; t 1/2 >20h) and altered (A; t 1/2 <20h) …

A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers

PD Martin, MJ Warwick, AL Dane, MV Cantarini - Clinical therapeutics, 2003 - Elsevier
Background: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,
has been developed for the treatment of patients with dyslipidemia. Objective: This study …

Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open …

MV Cantarini, T McFarquhar, RP Smith, C Bailey… - Clinical …, 2004 - Elsevier
BACKGROUND:: Many patients with head and neck cancer have difficulty swallowing tablet
formulations ofmedications, and use of dispersion preparations may be advantageous. …

Effect of oral linezolid on the pressor response to intravenous tyramine

MV Cantarini, CJ Painter, EM Gilmore… - British journal of …, 2004 - Wiley Online Library
Aims To investigate the effect of monoamine oxidase A inhibition from a single oral dose of
linezolid on the pressor response to intravenous (iv) tyramine, using positive and negative …

Circulating tumour-derived predictive biomarkers in oncology

…, R McCormack, M Malone, RE Board, MV Cantarini - Drug discovery today, 2010 - Elsevier
Molecular characterization of tumour material will become increasingly important in selecting
patients for clinical trials and offering appropriate treatment for patients in clinical practice. …

The relative bioavailability of gefitinib administered by granular formulation

MV Cantarini, CJ Bailey, B Collins, RP Smith - Cancer chemotherapy and …, 2008 - Springer
Background Gefitinib (IRESSA) is normally administered as a once-daily oral tablet. However,
many patients with head and neck cancer have difficulty swallowing medication in a tablet …